Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RINT1 deficiency disrupts lipid metabolism and underlies a complex hereditary spastic paraplegia
Nathalie Launay, … , Estela Area-Gomez, Aurora Pujol
Nathalie Launay, … , Estela Area-Gomez, Aurora Pujol
Published July 17, 2023
Citation Information: J Clin Invest. 2023;133(14):e162836. https://doi.org/10.1172/JCI162836.
View: Text | PDF
Research Article Metabolism Neuroscience Article has an altmetric score of 213

RINT1 deficiency disrupts lipid metabolism and underlies a complex hereditary spastic paraplegia

  • Text
  • PDF
Abstract

The Rad50 interacting protein 1 (Rint1) is a key player in vesicular trafficking between the ER and Golgi apparatus. Biallelic variants in RINT1 cause infantile-onset episodic acute liver failure (ALF). Here, we describe 3 individuals from 2 unrelated families with novel biallelic RINT1 loss-of-function variants who presented with early onset spastic paraplegia, ataxia, optic nerve hypoplasia, and dysmorphic features, broadening the previously described phenotype. Our functional and lipidomic analyses provided evidence that pathogenic RINT1 variants induce defective lipid–droplet biogenesis and profound lipid abnormalities in fibroblasts and plasma that impact both neutral lipid and phospholipid metabolism, including decreased triglycerides and diglycerides, phosphatidylcholine/phosphatidylserine ratios, and inhibited Lands cycle. Further, RINT1 mutations induced intracellular ROS production and reduced ATP synthesis, affecting mitochondria with membrane depolarization, aberrant cristae ultrastructure, and increased fission. Altogether, our results highlighted the pivotal role of RINT1 in lipid metabolism and mitochondria function, with a profound effect in central nervous system development.

Authors

Nathalie Launay, Montserrat Ruiz, Laura Planas-Serra, Edgard Verdura, Agustí Rodríguez-Palmero, Agatha Schlüter, Leire Goicoechea, Cristina Guilera, Josefina Casas, Felix Campelo, Emmanuelle Jouanguy, Jean-Laurent Casanova, Odile Boespflug-Tanguy, Maria Vazquez Cancela, Luis González Gutiérrez-Solana, Carlos Casasnovas, Estela Area-Gomez, Aurora Pujol

×

Figure 7

Pathogenic RINT1 variants lead to mitochondrial abnormalities.

Options: View larger image (or click on image) Download as PowerPoint
Pathogenic RINT1 variants lead to mitochondrial abnormalities.
(A) Repre...
(A) Representative images of mitochondrial network stained with MitoTracker Orange from control (CTL) and patient (P1 and P3) fibroblasts. Scale bar: 20 μm. A zoomed-in view is shown for each image; scale bar: 2 μm. (B) Quantification of the average mitochondrial size in control (CTL, n = 3) and patient (P1 and P3) fibroblasts. n > 20 cells for each genotype. (C) Quantification of mitochondrial number per cell in control (CTL, n = 3) and patient (P1 and P3) fibroblasts. n > 20 cells for each genotype. (D) Representative electron microscopy images displaying mitochondrial ultrastructure in control (CTL) and patient (P1 and P3) fibroblasts. Scale bar: 1 μm. A zoomed-in view is shown for each image; scale bar: 0.2 μm. Inter membrane space: blue; cristae: orange. (E) Percentage of damaged mitochondria in control (CTL, n = 3) and patient (P1 and P3) fibroblasts. n > 40 cells for each genotype. (F–H) ATP content (F) and depolarized mitochondrial (G) levels in patient (P1 and P3) fibroblasts compared with control (CTL, n = 5) fibroblasts. (H) Quantification of the intracellular ROS using the H2DCFDA probe in patient (P1 and P3) fibroblasts compared with control (CTL, n = 5) fibroblasts. All data are shown as the mean ± SD. Results were obtained from 2 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. Analysis of data were performed using 1-way ANOVA followed by Tukey’s test for multiple comparisons.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 26 news outlets
Posted by 28 X users
13 readers on Mendeley
See more details